{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:40:58Z","timestamp":1792608058017,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10549-021-06124-8","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T09:08:48Z","timestamp":1613725728000},"page":"667-676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer"],"prefix":"10.1007","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-5579","authenticated-orcid":false,"given":"Yihong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaljeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Yakirevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"6124_CR1","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L (2017) HER2-positive breast cancer. The Lancet 389:2415\u20132429","journal-title":"The Lancet"},{"key":"6124_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006242.pub2","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi B et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006242.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"6124_CR3","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659\u20131672","journal-title":"N Engl J Med"},{"issue":"16","key":"6124_CR4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673\u20131684","journal-title":"N Engl J Med"},{"issue":"6","key":"6124_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","volume":"15","author":"L Gianni","year":"2014","unstructured":"Gianni L, Eiermann W, Semiglazov V et al (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15(6):640\u2013647","journal-title":"Lancet Oncol"},{"key":"6124_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/jnci\/dji021","volume":"97","author":"D Mauri","year":"2005","unstructured":"Mauri D, Pavlidis N, Ioannidis J (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Institute 97:188\u2013194","journal-title":"J Natl Cancer Institute"},{"key":"6124_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377\u2013384","journal-title":"Lancet"},{"key":"6124_CR8","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J clin oncol 15:2483\u20132493","journal-title":"J clin oncol"},{"key":"6124_CR9","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","volume":"23","author":"A Buzdar","year":"2005","unstructured":"Buzdar A, Ibrahim N, Francis D et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J clin oncol 23:3676\u20133685","journal-title":"J clin oncol"},{"key":"6124_CR10","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","volume":"32","author":"J Baselga","year":"2014","unstructured":"Baselga J, Cortes J, Im SA et al (2014) Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32:3753\u20133761","journal-title":"J Clin Oncol"},{"issue":"28","key":"6124_CR11","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1200\/JCO.2008.21.4163","volume":"27","author":"WM Sikov","year":"2009","unstructured":"Sikov WM, Dizon DS, Strenger R et al (2009) Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 27(28):4693\u20134700","journal-title":"J Clin Oncol"},{"issue":"9","key":"6124_CR12","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of oncol 24(9):2278\u20132284","journal-title":"Annals of oncol"},{"key":"6124_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ctrv.2018.04.015","volume":"67","author":"JM Cejalvo","year":"2018","unstructured":"Cejalvo JM et al (2018) Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treat Rev 67:63\u201370","journal-title":"Cancer Treat Rev"},{"key":"6124_CR14","doi-asserted-by":"publisher","first-page":"GS3-02","DOI":"10.1158\/0008-5472.CAN-17-1923","volume":"78","author":"I Krop","year":"2018","unstructured":"Krop I et al (2018) Abstract GS3\u201302: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab. Cancer Res 78:GS3-02-GS3-02","journal-title":"Cancer Res"},{"issue":"1","key":"6124_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25\u201332","journal-title":"Lancet Oncol"},{"key":"6124_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1200\/JCO.2003.03.124","volume":"21","author":"HJ Burstein","year":"2003","unstructured":"Burstein HJ, Harris LN, Gelman R et al (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin\/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21:46\u201353","journal-title":"J Clin Oncol"},{"issue":"4","key":"6124_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.5858\/133.4.633","volume":"133","author":"S Sahoo","year":"2009","unstructured":"Sahoo S, Lester SC (2009) Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 133(4):633\u2013642","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"6124_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.5858\/134.6.907","volume":"134","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(6):907\u2013922","journal-title":"Arch Pathol Lab Med"},{"issue":"20","key":"6124_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105","journal-title":"J Clin Oncol"},{"key":"6124_CR20","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1200\/JCO.2011.36.0107","volume":"29","author":"CH Tse","year":"2011","unstructured":"Tse CH, Hwang HC, Goldstein LC et al (2011) Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol 29:4168\u20134174","journal-title":"J Clin Oncol"},{"key":"6124_CR21","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.breast.2015.07.011","volume":"24","author":"N Harbeck","year":"2015","unstructured":"Harbeck N (2015) Insights into biology of luminal HER2 vs. enriched HER2 subtypes: therapeutic implications. Breast 24:S44\u2013S48","journal-title":"Breast"},{"key":"6124_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"6124_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.00001","volume":"9","author":"S Pernas","year":"2019","unstructured":"Pernas S, Petit A, Climent F et al (2019) PAM50 subtype in baseline and residual tumors following neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer: A consecutive-series from a single institution. Frontiers Oncol 9:1\u201310","journal-title":"Frontiers Oncol"},{"key":"6124_CR24","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Trippa L, Barry W et al.TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT). SABCS19-GS1\u201305","DOI":"10.1158\/1538-7445.SABCS19-GS1-05"},{"key":"6124_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/modpathol.2016.175","volume":"30","author":"M Ballard","year":"2017","unstructured":"Ballard M, Jalikis F, Krings G et al (2017) \u2018Nonclassical\u2019 HER2 FISH results in breast cancer: Amultiinstitutional study. Mod Pathol 30:227\u2013235","journal-title":"Mod Pathol"},{"key":"6124_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14111-3","author":"F Bras\u00f3-Maristany","year":"2020","unstructured":"Bras\u00f3-Maristany F, Griguolo G, Pascual T et al (2020) Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-019-14111-3","journal-title":"Nat Commun"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-021-06124-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T05:13:36Z","timestamp":1671340416000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-021-06124-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["6124"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06124-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"24 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were under the institutional and\/or national research committee's ethical standards and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The human materials were obtained from archived paraffin blocks that were remnants of what was used for pathologic diagnosis. Informed consent was not required by the Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}